Biotage AB has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biotage AB (Uppsala, Sweden) has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biomolecules are one of the fastest growing areas in drug development today, offering potential treatments to medical conditions poorly served by traditional pharmaceuticals.
“This investment makes an exciting part of our long-term strategic efforts,” explained Torben Jörgensen, CEO of Biotage. “We already have products for drug development based on peptides and are now taking one step further towards strengthening Biotage’s future offering in the biomolecule purification area.”
The deal, which sees Biotage own approximately 22% of Chreto, allows Biotage access to a wealth of biomolecule purification knowledge, as well as novel and patent protected technology.
For more information on Biotage please visit: www.biotage.com
Analysis of Greenhouse Gases by Gas Chromatography
May 15th 2024This application note demonstrates the use of SCION's 8500GC system for the analysis of key greenhouse gases—carbon dioxide, methane, and nitrous oxide—in a single atmospheric air matrix. Highlighting the system's excellent sensitivity and repeatability, this method is crucial for understanding emission sources and combating climate change.
Analysis of DEHP in Drinking Water by HPLC-DAD
May 15th 2024This application note outlines a method for detecting low levels of 1,4-Dioxane, a likely carcinogenic compound, in drinking water using SCION GC-MS technology. It details the procedure for analyzing water samples spiked with 1,4-Dioxane, achieving excellent sensitivity and low detection limits, demonstrating the method's effectiveness for environmental monitoring.